← Eichor
Study identifier: NCT05536856 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Topical 5-Fluorouracil Effervescent Powder in the Treatment of Vitiligo

Condition: Vitiligo · Topical Fluorouracil · Effervescent Mixture  ·  Sponsor: Al-Azhar University

PhasePhase 4
Planned participants60
Who can joinAll sexes, 10 Years to 70 Years
Healthy volunteersNo

About this study

A novel approach for 5-Fluorouracil delivery based on a solid effervescent formulation is proposed . 5-Fluorouracil is water soluble (\~50mg/ml) and therefore has been used for the development of novel topical formulations including nano and microparticles intended for skin targeting. After hydration 5-Fluorouracil could form a complex, a suspension or even be formulated to generate effervescence. In effervescent technology, gas bubbles occur from the liquid after chemical reaction between alkali salts and organic acids (mainly citric or tartaric. Due to liberation in CO2 gas, the dissolution of drug in water is enhanced. The aim of this study is the development and clinical evaluation of topical 5-florouracil effervescent powder formulation in the treatment of vitiligo.

This description comes directly from the study's public registry record.

Talk to the study team

Neveen A. Kohaf, Ph.D  ·  +201069482380  ·  nevenabdo@azhar.edu.eg

Always discuss trial participation with your own doctor first.

Locations (1)

Facualty of Pharmacy, Al Azhar UniversityCairo, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05536856